Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
08:31am, Wednesday, 30'th Jul 2025
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
07:18am, Wednesday, 30'th Jul 2025
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
04:20am, Wednesday, 30'th Jul 2025
Often, great investing boils down to holding on to great stocks. It can be as simple as that.
Top 10 Income Funds From Eaton Vance
03:23pm, Tuesday, 29'th Jul 2025
Eaton Vance's top taxable closed-end funds offer reliable monthly income, strong long-term returns, and are managed by highly skilled teams with proven track records. I prioritize funds trading at a d
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed stati
Lilly's cancer drug more effective than AbbVie's in head-to-head study
07:05am, Tuesday, 29'th Jul 2025
Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when tested in patients with a type of blood cancer.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
02:06pm, Monday, 28'th Jul 2025
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
12:21pm, Monday, 28'th Jul 2025
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
11:31am, Monday, 28'th Jul 2025
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
The Smartest Dividend Stocks to Buy With $350 Right Now
04:50am, Saturday, 26'th Jul 2025
I like dividend stocks. You probably should, too, even if you aren't interested in the income they provide.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Thursday, 24'th Jul 2025
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I Switched from Mutual Funds to These 3 ETFs—Here’s Why
04:10pm, Wednesday, 23'rd Jul 2025
Key Points ETFs have generated higher returns than mutual funds. GLD, VYM, and QQQ have the potential to outpace S&P 500. Are you ahead, or behind on retirement? SmartAsset’s free tool can match
Final Trades: Abbvie, Uber, Western Union and Live Nation
01:25pm, Wednesday, 23'rd Jul 2025
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
06:46pm, Tuesday, 22'nd Jul 2025
AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
4 Reasons To Buy AbbVie
11:21am, Tuesday, 22'nd Jul 2025
I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine th
